Journal article

Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.

Eugene Schiff, Ching-Lung Lai, Stephanos Hadziyannis, Peter Neuhaus, Norah Terrault, Massimo Colombo, Hans Tillmann, Didier Samuel, Stefan Zeuzem, Jean-Pierre Villeneuve, Sarah Arterburn, Katyna Borroto-Esoda, Carol Brosgart, Steven Chuck, undefined Adefovir Dipivoxil Study 45 Intrnational Investigators Group

Liver Transpl | Published : 2007

Abstract

Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (<1,000 copies/mL) in 59% and 65% at weeks 48 and 96, respectively. After 48 weeks, alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 77%, 76%, 60%, and 84% of wait-listed patients, respectively. Among posttransplantation patients, serum HBV DNA levels became undetectable in 40% and 65% at weeks 48 and 96, respectively. After 48 weeks, ALT, albumin, bilirubin, ..

View full abstract

University of Melbourne Researchers